BioArctic
Develops treatments and diagnostics for neurodegenerative disorders like Alzheimer's and Parkinson's.
BIOA | ST
Overview
Corporate Details
- ISIN(s):
- SE0010323303 (+1 more)
- LEI:
- 549300Y0OI2WVUNHLC33
- Country:
- Sweden
- Address:
- Warfvinges väg 35, 112 51 Stockholm
- Website:
- https://www.bioarctic.se/en/
- Sector:
- Professional, scientific and technical activities
- Industry:
- Research and experimental development on natural sciences and engineering
Description
BioArctic is a Swedish research-intensive biopharmaceutical company focused on developing novel, disease-modifying treatments and diagnostics for neurodegenerative disorders. The company's core mission is to address the underlying causes of diseases such as Alzheimer's and Parkinson's. Its research is centered on developing innovative drugs and antibodies that target the root mechanisms of nerve cell damage and misfolded proteins, aiming to provide effective solutions for significant unmet medical needs within the central nervous system.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2022-07-06 01:30 |
FDA accepterar registreringsansökan och beviljar prioriterad granskning för lec…
|
Swedish | 195.0 KB | ||
| 2022-05-10 01:35 |
Eisai slutför stegvis ansökan till FDA av lecanemab för behandling av tidig Alz…
|
Swedish | 198.8 KB | ||
| 2022-05-10 01:35 |
Eisai completes rolling submission to the FDA of lecanemab for early Alzheimer’…
|
English | 199.0 KB | ||
| 2022-05-05 12:15 |
Kommuniké från årsstämma i BioArctic AB (publ)
|
Swedish | 166.1 KB | ||
| 2022-05-05 12:15 |
Report from annual general meeting in BioArctic AB (publ)
|
English | 167.7 KB | ||
| 2022-04-28 08:00 | Swedish | 803.7 KB | |||
| 2022-04-28 08:00 | English | 806.0 KB | |||
| 2022-04-20 07:50 |
AbbVie terminates collaboration with BioArctic on alpha-synuclein portfolio
|
English | 143.1 KB | ||
| 2022-04-20 07:50 |
AbbVie avslutar samarbetet med BioArctic kring alfa-synuklein-portföljen
|
Swedish | 143.8 KB | ||
| 2022-04-06 08:00 |
Notice of Annual General Meeting in BioArctic AB (Publ)
|
English | 241.0 KB | ||
| 2022-04-06 08:00 |
Kallelse till årsstämma i BioArctic AB (publ)
|
Swedish | 170.3 KB | ||
| 2022-03-31 08:02 | Swedish | 25.2 MB | |||
| 2022-03-09 08:00 |
The Nomination Committee's proposal for the election of board members in BioArc…
|
English | 180.3 KB | ||
| 2022-03-09 08:00 |
Valberedningens förslag till val av styrelseledamöter i BioArctic AB
|
Swedish | 159.8 KB | ||
| 2022-03-04 00:47 |
Eisai initiates submission of application data of lecanemab under the prior ass…
|
English | 196.2 KB |
Automate Your Workflow. Get a real-time feed of all BioArctic filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for BioArctic
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for BioArctic via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2025-02-13 | Gunilla Osswald | Other | Sell | 40,000 | 8,821,200.00 SEK |
| 2025-02-13 | Gunilla Osswald | Other | Other | 40,000 | 3,344,000.00 SEK |
| 2025-02-13 | Sten Mikael Moge | Other | Sell | 6,000 | 1,323,180.00 SEK |
| 2025-02-13 | Sten Mikael Moge | Other | Other | 6,000 | 501,600.00 SEK |
| 2025-02-13 | Johanna Margareta Fälting | Other | Sell | 1,500 | 330,795.00 SEK |
| 2025-02-13 | Johanna Margareta Fälting | Other | Other | 2,500 | 209,000.00 SEK |
| 2025-02-13 | Johanna Margareta Fälting | Other | Other | 1,500 | 125,400.00 SEK |
| 2025-01-10 | Mikael Smedeby | Other | Buy | 730 | 148,920.00 SEK |
| 2024-12-19 | Oskar Bosson | Other | Sell | 2,000 | 446,000.00 SEK |
| 2024-12-19 | Oskar Bosson | Other | Sell | 871 | 195,626.60 SEK |
Peer Companies
